MedTrace Logo

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT07622186 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-06-03

No results posted yet for this study

Summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Conditions

Interventions

DRUG

SKB571 for injection

Intravenous(IV) infusion(Q3W)

DRUG

Osimertinib

orally once daily

DRUG

Furmonertinib

orally once daily

DRUG

carboplatin

Intravenous(IV) infusion(Q3W)

DRUG

Cisplatin

Intravenous(IV) infusion(Q3W)

DRUG

Pembrolizumab

Intravenous(IV) infusion(Q3W)

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xin Li, MD · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07622186 on ClinicalTrials.gov